EQT Life Sciences led a $56m Series D round in Neuros Medical.

EQT Life Sciences, a European healthcare investor, led a $56m Series D round in Neuros Medical, a commercial-stage medical technology company, with participation from US Venture Partners, Amzak Health, Osage University Partners, Sectoral Asset Management, and Aperture Venture Partners. “I would like to thank our new and existing investors for their support in our mission to relieve pain and restore life for the millions of people suffering from chronic post-amputation pain. This funding round is a strong validation of the unmet medical need in the amputee community and allows us to scale our commercial operations to expand access to this breakthrough technology, while equipping healthcare professionals with a non-opioid solution and support they need to deliver the highest standard of care," David Veino, Neuros Medical President & CEO.